Anti-Mouse TIM3 PE 100 ug
- Known as:
- Antibody toMouse TIM3 PE 100 ug
- Catalog number:
- 12-5871-82
- Category:
- -
- Supplier:
- eBioscience
- Gene target:
- Anti-Mouse TIM3 100
Related genes to: Anti-Mouse TIM3 PE 100 ug
- Gene:
- HAVCR2 NIH gene
- Name:
- hepatitis A virus cellular receptor 2
- Previous symbol:
- -
- Synonyms:
- Tim-3, TIM3, FLJ14428, TIMD3, CD366
- Chromosome:
- 5q33.3
- Locus Type:
- gene with protein product
- Date approved:
- 2002-12-04
- Date modifiied:
- 2018-06-27
Related products to: Anti-Mouse TIM3 PE 100 ug
Related articles to: Anti-Mouse TIM3 PE 100 ug
- Regulatory T cells (Tregs) may influence prognosis in leukemia. This study aimed to explore the effects and mechanisms of Treg subclusters on the prognosis in B-cell acute lymphoblastic leukemia (B-ALL) using single-cell RNA sequencing (scRNA-Seq). - Source: PubMed
Publication date: 2026/07/28
Songnan SuiZheng JiamianLai JingZhang YupeiJiang XuXu LingZhong LiyeChen JieWu JieZhu XunLi YangqiuWu GuocaiChen Zhanghui - Peripheral T-cell lymphoma (PTCL) is a heterogeneous and highly aggressive subtype of non-Hodgkin lymphoma. Approximately 30% of patients develop relapsed or refractory PTCL (R/R PTCL) due to disease recurrence or failure to achieve complete remission after first-line therapy. Despite therapeutic advances, the molecular and cellular mechanisms underlying treatment resistance in R/R PTCL remain unclear. - Source: PubMed
Publication date: 2026/07/10
Zhang NingYu JingweiLiu HengqiHu ZechaoMeng ShenSun CongLu YaxiaoLiu XiaSong ZhengLi LanfangQiu LihuaQian ZhengziMeng BinGong WenchenZhou ShiyongWang XianhuoZhang Huilai - Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with a unique tumor microenvironment, and while Programmed cell death protein 1/Programmed cell death ligand 1 (PD-1/PD-L1) blockade represents a standard immunotherapy, most patients develop primary or acquired resistance, with few alternative immunotherapeutic targets currently available. Therefore, we aimed to identify potential immune checkpoint-related molecules involved in TNBC-macrophage crosstalk, clarify the underlying molecular mechanism mediated by small extracellular vesicles (sEVs), and provide a theoretical basis for the future development of novel immunotherapeutic targets against TNBC. Single-cell RNA-sequencing (scRNA-seq) datasets for various breast cancer subtypes were used. Pseudotime trajectory, cell‒cell communication and Tumor Immune Estimation Resource 2.0 (TIMER2) analyses were conducted to characterize the tumour microenvironment (TME). Immunochemistry and immunofluorescence were used to confirm the results of the above analyses. Single-nucleus RNA sequencing (snRNA-seq) was conducted on three pairs of TNBC tumour and adjacent normal tissues. The functions of tumour-associated macrophages (TAMs) and sEVs in TNBC metastasis were explored by Western blotting, flow cytometry and cell-based experiments. A total of nearly 60,000 high-quality single cells were subjected to scRNA-seq analysis, from which seven major cell types were identified. An overall increase in immune cell proportion was observed in TNBC compared with other subtypes, with the immune cell fraction in TNBC tissues being ~1.8-fold higher than that in luminal A/HER2+ subtypes ( < 0.001). Cell‒cell communication analysis indicated that TNBC cells mainly interact with macrophages. Interestingly, HAVCR2, an immune checkpoint, is expressed mainly in macrophages in the TNBC TME. HAVCR2 is associated with macrophage pseudotime progression in TNBC, which was validated by immunofluorescence staining. Moreover, analysis of The Cancer Genome Atlas (TCGA) bulk RNA-seq data revealed that HAVCR2 expression is significantly correlated with M2-like macrophage gene signatures and computationally inferred macrophage infiltration levels in TNBC, and this tissue-level transcriptional correlation is associated with poor patient prognosis. Notably, bulk RNA-seq data cannot define discrete cell subsets, and the identification of HAVCR2+ M2 macrophage subsets was independently validated by scRNA-seq and snRNA-seq at the single-cell level. Furthermore, treatment with TNBC-derived sEVs is associated with concurrent increases in the expression of HAVCR2 and M2-associated markers (CD163, CD206) in macrophages. These findings reflect a correlative association rather than a demonstrated causal or regulatory relationship between HAVCR2 and M2-associated marker upregulation. sEVs derived from TNBC cells are associated with the upregulation of M2-associated markers and concomitant HAVCR2 upregulation in macrophages, both of which correlate with TNBC progression and metastasis. We propose that HAVCR2 may serve as a candidate prognostic marker associated with M2-like macrophage features in TNBC, and these foundational findings from Human acute monocytic leukemia cell line (THP-1) macrophages warrant further validation in primary human monocyte-derived macrophages and TNBC models. - Source: PubMed
Publication date: 2026/07/16
Liu JiaWang BinqianJin YannanChen WenquanShi RuohanWang WeijiaZhang XiaojingTan YiMan ZhongranHu BoZhu LisenZhang BiaoBao ChongchanJin Gongsheng - Uncoupling protein 2 (UCP2) has been extensively studied as a metabolic regulator in glioma; however, its relationship with the tumour immune microenvironment and the cellular source of its expression within the glioma tumour microenvironment (TME) remains poorly understood. This study aimed to characterise UCP2 expression at single-cell resolution and evaluate its immunological significance in glioma. - Source: PubMed
Publication date: 2026/07/16
Zhou HuiWang JiaruiQiao ZhiliLiao Xin - To investigate the expression pattern of Erb-B2 receptor tyrosine kinase 2 () in bladder urothelial carcinoma (BLCA) and its clinical relevance, prognostic value, and potential molecular mechanisms, thereby providing evidence for biomarker identification and targeted therapy research in BLCA. - Source: PubMed
Zheng GuangweiPeng YunDU YiqingXu Tao